Back to search

Peptide record

TPDB11450

Pardaxin Pardaxin-1 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
33 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11450
Pardaxin Pardaxin-1
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifp Antifungipept AI4AVP dbAMP 3.0 DRAVP 2.0 APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 33-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE
Physicochemical Analysis
C154H248N36O45
RNDCHMWY
S
3323.88
9.88
2
1
15
+1
-0.99
0.745
112.42
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
9
Residue Composition
number
3
A
0
R
0
N
0
D
0
C
1
E
1
Q
4
G
0
H
3
I
5
L
2
K
0
M
3
F
2
P
7
S
1
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 3 R: 0 N: 0 D: 0 C: 0 E: 1 Q: 1 G: 4 H: 0 I: 3 L: 5 K: 2 M: 0 F: 3 P: 2 S: 7 T: 1 W: 0 Y: 0 V: 1
Chemical Descriptors
33
C154H248N36O45
3323.88
9.88
+1
-0.99
0.745
Free
L
Linear
Free
Antibacterial Antimicrobial
Red Sea Mosessole Epinephelus nebulosus Pardachirus marmoratus
Evidence Records 49 records
Evidence 1 Activity

Activity

IC50
IC50=15.74 µg/ml
Anticancer
15.74 µg/mL

Target

Fibrosarcoma
HT-1080
Not Available

Assay & Model

MTT/MTS assay
3-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 2 Activity

Activity

IC50
IC50=15.40 µg/ml
Anticancer
15.40 µg/mL

Target

Fibrosarcoma
HT-1080
Not Available

Assay & Model

MTT/MTS assay
6-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 3 Activity

Activity

IC50
IC50=14.51 µg/ml
Anticancer
14.51 µg/mL

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
12-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 4 Activity

Activity

IC50
IC50=14.52 µg/ml
Anticancer
14.52 µg/mL

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 5 Activity

Activity

62 % Cytotoxicity at 50 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
3-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 6 Activity

Activity

44 % Cytotoxicity at 25 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
3-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 7 Activity

Activity

4 % Cytotoxicity at 12.5 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
3-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 8 Activity

Activity

75 % Cytotoxicity at 50 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
6-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 9 Activity

Activity

70 % Cytotoxicity at 25 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
6-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 10 Activity

Activity

4 % Cytotoxicity at 3.125 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
6-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 11 Activity

Activity

78 % Cytotoxicity at 50 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
12-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 12 Activity

Activity

68 % Cytotoxicity at 25 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
12-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 13 Activity

Activity

4 % Cytotoxicity at 12.5 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
12-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 14 Activity

Activity

5 % Cytotoxicity at 6.25 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
12-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 15 Activity

Activity

10 % Cytotoxicity at 3.125 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
12-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 16 Activity

Activity

90 % Cytotoxicity at 50 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 17 Activity

Activity

80 % Cytotoxicity at 25 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 18 Activity

Activity

15 % Cytotoxicity at 12.5 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 19 Activity

Activity

12 % Cytotoxicity at 6.25 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 20 Activity

Activity

5 % Cytotoxicity at 3.125 mg/L
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 21 Activity

Activity

88 % Cytotoxicity at 50 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
3-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 22 Activity

Activity

82 % Cytotoxicity at 25 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
3-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 23 Activity

Activity

40 % Cytotoxicity at 12.5 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
3-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 24 Activity

Activity

35 % Cytotoxicity at 6.25 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
3-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 25 Activity

Activity

35 % Cytotoxicity at 3.125 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
3-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 26 Activity

Activity

90 % Cytotoxicity at 50 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
6-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 27 Activity

Activity

90 % Cytotoxicity at 25 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
6-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 28 Activity

Activity

30 % Cytotoxicity at 12.5 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
6-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 29 Activity

Activity

30 % Cytotoxicity at 6.25 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
6-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 30 Activity

Activity

30 % Cytotoxicity at 3.125 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
6-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 31 Activity

Activity

97 % Cytotoxicity at 50 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
12-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 32 Activity

Activity

95 % Cytotoxicity at 25 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
12-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 33 Activity

Activity

39 % Cytotoxicity at 12.5 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
12-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 34 Activity

Activity

28 % Cytotoxicity at 6.25 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
12-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 35 Activity

Activity

38 % Cytotoxicity at 3.125 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
12-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 36 Activity

Activity

90 % Cytotoxicity at 50 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 37 Activity

Activity

90 % Cytotoxicity at 25 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 38 Activity

Activity

15 % Cytotoxicity at 12.5 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 39 Activity

Activity

5 % Cytotoxicity at 6.25 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 40 Activity

Activity

10 % Cytotoxicity at 3.125 mg/L
Anticancer

Target

Fibrosarcoma
HT-1080
Fibrous connective tissue

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 41 Activity

Activity

Cell Viability
Cell Viability <20% at 20µg/mL
Anticancer
<20 % at 20µg/mL

Target

Oral cancer
OSCC-SCC-4
Not Available

Assay & Model

MTT assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2015
Evidence 42 Activity

Activity

50% Cytotoxicity
Toxicity
19.5±3.2 µg/mL
Cytotoxic
50% Cytotoxicity | 19.5±3.2 | µg/mL | target cell: Baby Hamster Kidney cells BHK-21

Target

Baby Hamster Kidney cells BHK-21

Source & Reference

NA
DBAASP
Grouper (Epinephelus coioides) antimicrobial peptide epinecidin-1 exhibits antiviral activity against foot-and-mouth disease virus in vitro. | Peptides | 2018
Evidence 43 Activity

Activity

<10% Hemolysis
Toxicity
10 µM
Hemolytic Cytotoxic
<10% Hemolysis | 10 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A class of highly potent antibacterial peptides derived from pardaxin, a pore-forming peptide isolated from Moses sole fish Pardachirus marmoratus. | Eur J Biochem | 1996
Evidence 44 Activity

Activity

50% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
50% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A class of highly potent antibacterial peptides derived from pardaxin, a pore-forming peptide isolated from Moses sole fish Pardachirus marmoratus. | Eur J Biochem | 1996
Evidence 45 Activity

Activity

50% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 100 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Truncated antimicrobial peptides from marine organisms retain anticancer activity and antibacterial activity against multidrug-resistant Staphylococcus aureus. | Peptides | 2013
Evidence 46 Activity

Activity

50% Hemolysis
Toxicity
5 µM
Hemolytic Cytotoxic
50% Hemolysis | 5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evidence 47 Activity

Activity

100% Hemolysis
Toxicity
10 µM
Hemolytic Cytotoxic
100% Hemolysis | 10 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A class of highly potent antibacterial peptides derived from pardaxin, a pore-forming peptide isolated from Moses sole fish Pardachirus marmoratus | Eur J Biochem | 1996
Evidence 48 Activity

Activity

% Hemolysis
Toxicity
7 %
Hemolytic
Hemolytic_activity: [Ref.23598079] 7% hemolysis at 12.5 mg/L , 10% hemolysis at 25 mg/L , 27% hemolysis at 50 mg/L , 55% hemolysis at 100 mg/L , 95% hemolysis at 200 mg/L , 90% hemolysis at 400 mg/L against sheep red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Biophys J. 2002 Aug 83(2):1004-1013.##J Biol Chem. 2010 Feb 5 285(6):3883-3895.##J Biol Chem. 2004 Oct 29 279(44):45815-23.##Peptides. 2013 Jun 44:139-48.
Evidence 49 Hemolysis

Source & Reference

APD_complete HemoPI PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.